NCT02876796 - Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

October 31, 2015

Conditions

PD Effects of GS-0976 (NDI-010976) on Fractional DNL

Interventions

DRUG

GS-0976

Capsule(s) administered orally

DRUG

Placebo

Capsule(s) administered orally

OTHER

1-13C acetate

10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours

OTHER

Fructose solution

Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses

Trial Locations (1)

Phoenix